Sanofi (SNY), a biopharmaceutical company, announced that it has priced its offering of 2.3 billion Euros of notes across 3 tranches. Sanofi intends to use the net proceeds of the offering for general corporate purposes.
Sanofi develops and markets medicines and vaccines across areas including immunology, oncology, and rare diseases.
The pricing of notes across three tranches is such that,
-1,000 million Euros fixed-rate notes, which are due May 2029, bearing interest at an annual rate of 3.000%.
-650 million Euros fixed-rate notes, which are due May 2033, bearing interest at an annual rate of 3.375%.
-650 million Euros fixed-rate notes, due May 2037, bearing interest at an annual rate of 3.750%.
The notes are being issued under Sanofi's Euro Medium Term Note programme, and the transaction has been led by Citigroup, HSBC, and J.P. Morgan as global coordinators.
Sanofi offers vaccines for poliomyelitis, pertussis, Haemophilus influenzae type b (Hib) pediatric vaccines, and protection against respiratory syncytial virus.
SNY has traded between $43.32 and $55.73 over the past year. The stock closed Friday's trade at $46.78, down 1.58%.
In the overnight market, SNY is down 1.47% at $46.09.
For More Such Biotech Stock News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.